Therapy Areas: Inflammatory Diseases
CEL-SCI Receives Patent for LEAPS Vaccine Platform Aimed at Influenza, Other Infectious Diseases
5 February 2018 - - The US Patent and Trademark Office has allowed Vienna, Virginia-based drug and vaccine developer CEL-SCI Corp. (NYSE American: CVM) a patent titled, "Method for Inducing an Immune Response and Formulations Thereof" for its LEAPS technology, the company said.
CEL-SCI's patented invention relates to methods for diagnosing, preventing, and treating disease by generating or modulating the immune response through the use of specific peptides.
This specific allowed patent expands the LEAPS platform technology protection by addressing the invention's methods for diagnosing, preventing and treating infectious diseases, including using cellular delivery approaches, with indications such as influenza, including swine and avian flu, other viruses such as herpes, and also bacteria and parasites.
The LEAPS platform technology is currently being developed as a therapeutic vaccine for rheumatoid arthritis under a USD1.5 m grant from the US National Institutes of Health.
LEAPS is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. LEAPS compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases.
The company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.